ClinicalTrials.gg
RecruitingNCT06393738Updated Nov 20, 2026

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

A Phase 1 interventional study of ARV-393 and Glofitamab in Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) and Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL), sponsored by Arvinas Inc.. Recruiting at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Arvinas Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 20, 2026First sites in Israel and ItalyPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
329
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option.

ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

Read the detailed description

This is an open-label, global, multi-center monotherapy and combination dose escalation and dose optimization study to evaluate safety, tolerability and preliminary efficacy of ARV-393. The study will evaluate the safety and tolerability in ascending doses of ARV-393 as monotherapy (A) and in combination with glofitamab (C), as well as determine the RP2D in the dose optimization parts (B for monotherapy) and in combination with glofitamab (D for combination therapy). The monotherapy portions of the study will include participants with R/R NHL. The combination therapy portions of the study with glofitamab will include participants with R/R DLBCL.

02

Conditions studied

  • Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
  • Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Keywords

  • Relapsed/Refractory B cell Non Hodgkin Lymphoma (NHL)
  • Relapsed/Refractory Angioimmunoblastic T-cell lymphoma (AITL)
  • Advanced non-Hodgkin Lymphoma
  • advanced NHL
  • relapsed non-Hodgkin Lymphoma
  • refractory non-Hodgkin Lymphoma
  • B Cell Advanced Non-Hodgkin Lymphoma
03

In context

Lead sponsor

Arvinas Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Part A and B: Have NHL and >=2 prior systemic therapies, (including rituximab), and be ineligible for known therapies with demonstrated clinical benefit per investigator assessment or, confirmed AITL that has recurred or progressed following institutional standard of care therapy.
  • For Part C and D: Have R/R DLBCL, not otherwise specified [NOS (DLBCL, NOS)] or large B-cell lymphoma (LBCL) arising from follicular lymphoma and have received two or more .
  • Have at least one bi dimensionally >1.5-centimeter (cm) in largest dimension for nodal or >1.0 cm for extranodal lesion.
  • (ECOG) performance status (PS) of 0 or 1 (NOTE: For Part A only - ECOG PS of 2 is allowed for participants with secondary CNS lymphoma).
  • Adequate bone marrow function
  • Adequate kidney function
  • Adequate Liver Function

Exclusion criteria

Exclusion Criteria:

  • Current or past history of peripheral eosinophilia, hypereosinophilic syndrome (HES), organ-specific eosinophilic disorder, or drug reaction with eosinophilia and systemic symptoms (DRESS), except for peripheral eosinophilia due to disease under study. Participants with current or prior eosinophilia requiring systemic treatment are excluded regardless of etiology.
  • Prior stem cell transplant (SCT) or solid organ transplantation.
  • Prior treatment with chimeric antigen receptor (CAR) T-cell therapy within 60 days prior to Cycle 1 Day 1 (C1D1) or any prior treatment with a BCL6-targeted therapy
  • Any other active within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, melanoma in situ or carcinoma in situ of the breast or cervix, and prostate cancer with active surveillance.
  • Any of the following in the previous 6 months:

    • Myocardial infarction, long syndrome or family history of long QT syndrome, or Torsade de Pointes;
    • atrial or ventricular arrhythmias;
    • Serious conduction system abnormalities, 3rd degree atrioventricular (AV block), unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF), Class III or IV;
    • Cerebrovascular accident, , symptomatic pulmonary embolism, and/or other clinically significant episode of thromboembolic disease;
  • Active inflammatory gastrointestinal (GI) disease, chronic diarrhea, previous gastric resection, or lap band surgery.
  • Uncontrolled hypertension despite optimal medical treatment
  • History of myocarditis.
  • In ability to comply with listed prohibited treatments.
  • Standard 12-lead (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  • Cardiac \<45%.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
329 participants (estimated)

Study arms

  • Experimental
    Part A Monotherapy Dose escalation

    Participants with R/R NHL will receive ARV-393 dose escalation beginning at dose level 1

    Drug: ARV-393

  • Experimental
    Part B Monotherapy: Dose expansion/optimization

    Dose expansion and optimization of ARV-393 will be conducted in Part B to determine the recommended phase 2 dose (RP2D) for participants with R/R NHL

    Drug: ARV-393

  • Experimental
    Part C Combination therapy: Dose escalation

    Participants with R/R diffuse large B-cell lymphoma (DLBCL) will receive ARV-393 in combination with glofitamab, beginning at an ARV-393 dose informed by the Part A. Glofitamab will be given per labelled prescribing information. Part C will be conducted in non-USA centers.

    Drug: ARV-393 · Drug: Glofitamab

  • Experimental
    Part D Combination therapy: Dose expansion/optimization

    Part D will be an optimization of ARV-393 in combination with glofitamab to determine a potential RP2D for ARV-393 in the combination regimen. Part D will be conducted in non-USA centers in participants with R/R DLBCL.

    Drug: ARV-393 · Drug: Glofitamab

Interventions

  • DrugARV-393

    Oral daily dose of ARV-393 at a specified dose level

  • Glofitamab infusion per labelled prescribing information

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities During First 28 Days

    Percentage of participants in dose escalation arm at a given dose cohort with AEs meeting protocol defined dose limiting toxicities during cycle 1 (28 days)

    Time frame: 28 days from first study dosing

  2. Percentage of Participants With Adverse Events Characterized by Severity, Seriousness, and Relationship to Study Drug as a Measure of Safety and Tolerability

    Adverse events as characterized by type, frequency, severity, seriousness, and relationship to study drug

    Time frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393

  3. Number of Participants With Abnormal Vital Signs, Abnormal ECG Readings (QT Interval) and Abnormal Laboratory Parameters

    Shifts in vital signs, ECGs, and laboratory parameters from study baseline

    Time frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393

  4. Percentage of Participants With Grade 3 or Grade 4 Clinical Lab Abnormalities Using the Common Terminology Criteria for Adverse Events (CTCAE) With Scale From Grade 1 Grade 5. Higher Score Means Worse Outcome

    Incidence of Grade 3 and Grade 4 clinical laboratory abnormalities

    Time frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393

Secondary outcomes

  1. Area Under the Curve to the End of the Dosing Period (Auctau) for ARV-393

    Assessment of pharmacokinetic parameter AUC

    Time frame: 4 months from first drug dosing

  2. Area Under the Concentration Versus Time Curve, from 0 To Last Measurable Concentration (AUC0-Last) for ARV-393

    Assessment of pharmacokinetic parameter AUC

    Time frame: Time Frame: 4 months from first drug dosing

  3. Maximum Concentration (Cmax) for ARV-393

    Cmax is an assessment of pharmacokinetic parameter

    Time frame: 4 months from first drug dosing

  4. Minimum Concentration (Cmin) for ARV-393

    Cmin is an assessment of pharmacokinetic parameter

    Time frame: 4 months from first drug dosing

  5. Time to Maximum Concentration (Tmax) for ARV-393

    Tmax is an assessment of pharmacokinetic parameter

    Time frame: 4 months from first drug dosing

  6. Oral Clearance (CL/F) for ARV-393

    CL/F is an assessment of pharmacokinetic parameter

    Time frame: 4 months from first drug dosing

  7. Volume of Distribution (Vd/F) for ARV-393

    Vd/F is a proportionality factor that relates the amount of drug in the body to the concentration of drug measured in a biological fluid.

    Time frame: 4 months from first drug dosing

  8. Overall Response Rate (ORR) Based on Investigator Assessments of Response According to Lugano Response Criteria for NHL and International Primary Central Nervous System Lymphoma (PCNSL) Criteria for Central Nervous System (CNS Lymphoma), if Applicable

    ORR is a parameter measuring the anti-tumor activity of the study intervention. It is the percentage of participants reaching a complete response or partial response to the study treatment.

    Time frame: Approximately 2 years

  9. Complete Response Rate (CRR) Based on Investigator Assessments of Response According to the Lugano Response Criteria for NHL and the International PCNSL Criteria for CNS Lymphoma, if Applicable

    CRR is a parameter measuring the anti-tumor activity of the study intervention. CRR is percentage of participants with best of response reported as complete response.

    Time frame: Approximately 2 years

  10. Duration of Response (DOR) Based on Investigator Assessments of Response According to the Lugano Response Criteria for NHL and the International PCNSL Criteria for CNS Lymphoma, if Applicable

    DOR is the time from the initial response (CR or PR) to the date of progression, or death, whichever occurs first. It is a parameter measuring the anti-tumor activity of the study intervention.

    Time frame: Approximately 2 years

07

Study locations

27 of 28 sites recruiting
  • Clinical Trial Site
    New Haven, Connecticut 06510, United States
    Recruiting
  • Clinical Trial Site
    Miami, Florida 33136, United States
    Recruiting
  • Clinical Trial Site
    Detroit, Michigan 48201, United States
    Recruiting
  • Clinical Trial Site
    New Brunswick, New Jersey 10065, United States
    Recruiting
  • Clinical Trial Site
    New York, New York 10016, United States
    Recruiting
  • Clinical Trial Site
    New York, New York 10021, United States
    Recruiting
  • Clinical Trial Site
    Cleveland, Ohio 44122, United States
    Recruiting
  • Clinical Trial Site
    Nashville, Tennessee 37203, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinical Trial Site
    Houston, Texas 77030, United States
    Recruiting
  • Clinical Trial Site
    Charlottesville, Virginia 22908, United States
    Recruiting
  • Clinical Trial Site
    Brisbane, Queensland 4101, Australia
    Recruiting
  • Clinical Trial Site
    Ballarat, Victoria 3350, Australia
    Recruiting
  • Clinical Trial SIte
    East Melbourne, Victoria 3002, Australia
    Recruiting
  • Clinical Trial SIte
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
  • Clinical Trial Site
    Toronto, Ontario M5G 1Z5, Canada
    Recruiting
  • Clinical Trial Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Clinical Trial Site
    Copenhagen, 2100, Denmark
    Recruiting
  • Clinical Trial Site
    Odense C, 5000, Denmark
    Recruiting
  • Clinical Trial Site
    Jerusalem, 9112001, Israel
    Recruiting
  • Clinical Trial Site
    Tel Aviv, Israel
    Recruiting
  • Clinical Trial Site
    Candiolo, Torino 10060, Italy
    Recruiting
  • Clinical Trial Site
    Bologna, 40138, Italy
    Recruiting
  • Clinical Trial Site
    Milan, 20141, Italy
    Recruiting
  • Clinical Trial Site
    El Palmar, Murcia 30120, Spain
    Recruiting
  • Clinical Trial Site
    Pamplona, Navarre 31008, Spain
    Recruiting
  • Clinical Trial Site
    Barcelona, 8908, Spain
    Recruiting
  • Clinical Trial Site
    Madrid, 28050, Spain
    Recruiting
  • Clinical Trial Site
    Salamanca, 37007, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Dec 2028, 51 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Mar 2028 → Dec 2028 and completion Mar 2028 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
May 1, 2024
StartActual
Sep 5, 2024
Primary completionEst.
Dec 2028was Mar 2028
CompletionEst.
Dec 2030was Mar 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added — first sites in Israel and Italy
Show 7 added (3 Italy, 2 Australia, 2 Israel)
  • Clinical Trial Site · Brisbane, Australia
  • Clinical Trial Site · Ballarat, Australia
  • Clinical Trial Site · Jerusalem, Israel
  • Clinical Trial Site · Tel Aviv, Israel
  • Clinical Trial Site · Candiolo, Italy
  • Clinical Trial Site · Bologna, Italy
  • Clinical Trial Site · Milan, Italy
Nov 20, 2026
Primary completion
Mar 2028→Dec 2028
Nov 20, 2026
Study completion
Mar 2028→Dec 2030
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    7 sites added — first sites in Israel and Italy
    Show 7 added (3 Italy, 2 Australia, 2 Israel)
    • Clinical Trial Site · Brisbane, Australia
    • Clinical Trial Site · Ballarat, Australia
    • Clinical Trial Site · Jerusalem, Israel
    • Clinical Trial Site · Tel Aviv, Israel
    • Clinical Trial Site · Candiolo, Italy
    • Clinical Trial Site · Bologna, Italy
    • Clinical Trial Site · Milan, Italy
    Primary completion Mar 2028→Dec 2028
    Study completion Mar 2028→Dec 2030
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06393738
Lead sponsor
Arvinas Inc.
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Sep 5, 2024
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Arvinas Operations, Inc.
Contact
clinicaltrialsARV-393@arvinas.com
475-345-0791

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion